Enveda Biosciences vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 36)
Enveda Biosciences logo

Enveda Biosciences

EmergingLife Sciences & BioTech

Natural Product Drug Discovery — AI & Metabolomics Platform

Enveda Biosciences uses AI, metabolomics, and robotics to mine natural products for novel drug candidates; platform identifies chemical structure and activity from complex biological samples; raised $51M Series B in 2023;

AI VisibilityBeta
Overall Score
D36
Category Rank
#78 of 198
AI Consensus
89%
Trend
stable
Per Platform
ChatGPT
37
Perplexity
36
Gemini
34

About

Enveda Biosciences is a drug discovery company founded in 2020 and headquartered in Boulder, Colorado, that is revitalizing natural product chemistry as a source of novel pharmaceutical compounds using modern AI and metabolomics. Natural products — molecules produced by plants, fungi, bacteria, and other organisms — have historically been the origin of over 60% of approved drugs, including penicillin, aspirin, morphine, and paclitaxel. However, traditional natural product discovery was slow, requiring isolation and purification of individual compounds from complex biological mixtures before testing. Enveda's platform eliminates this bottleneck by using mass spectrometry, machine learning, and robotics to identify the chemical structure, biological activity, and function of molecules directly from complex natural samples — without requiring isolation of individual compounds first.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#78
Category Rank
#11
89
AI Consensus
68
stable
Trend
stable
37
ChatGPT
71
36
Perplexity
68
34
Gemini
80
38
Claude
77
34
Grok
69

Key Details

Category
Natural Product Drug Discovery — AI & Metabolomics Platform
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.